Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately define subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy for these cancers.

Speaker 2: (00:32)
 Could you provide a brief background about yourself?

 

Speaker 2: (01:12)
 Would you give us an overview of the PM3CX test?

 

Speaker 2: (03:02)
 Which patients should have this testing? 

 

Speaker 2: (05:14)
 Is this test qualitative and RNA?

 

Speaker 2: (06:35)
 After determining if it's primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma, does the test identify the cell of origin?

 

Speaker 2: (08:09)
 For patients diagnosed with diffuse large B-cell lymphoma, what are the treatment recommendations?

 

Speaker 2: (09:04)

Are there any other insights about this test that you'd like to share?